冠心宁注射液联合沙库巴曲缬沙坦治疗冠心病合并充血性心力衰竭的临床疗效及对患者心功能、心肌损伤指标的影响

doi:10.3969/j.issn.1671-7171.2026.06.007

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1216 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical efficacy of Guanxinning Injection combined with Sacubitril/Valsartan in the treatment of coronary heart disease complicated with congestive heart failure and its effects on cardiac function and myocardial injury markers. 【Methods】 A total of 110 patients with coronary heart disease complicated with congestive heart failure admitted to two hospitals from July 2024 to June 2025 were enrolled. The patients were randomly divided into an observation group and a control group using a random number table method, with 55 cases in each group. The control group received Sacubitril/Valsartan on the basis of conventional treatment, while the observation group received Guanxinning Injection in addition to the treatment of the control group. The clinical efficacy, cardiac function indicators [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD)], myocardial injury markers [N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin T (cTnT), cardiac troponin I (cTnI)], and the incidence of adverse reactions were compared between the two groups. 【Results】 The total clinical effective rate in the observation group was 96.36%(53/55), which was higher than that in the control group [85.45%(47/55)], and the difference was statistically significant (χ²=3.960, P<0.05). After treatment, LVEF in both groups was higher than that before treatment, while LVEDD and LVESD were shorter than those before treatment; The observation group showed higher LVEF and shorter LVEDD and LVESD compared with the control group, with statistically significant differences (P<0.05). After treatment, the serum levels of NT-proBNP, cTnT, and cTnI in both groups were lower than those before treatment, and these levels in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.909, P>0.05). 【Conclusion】 The combination of Guanxinning injection and sacubitril/valsartan demonstrates favorable efficacy in patients with coronary heart disease and congestive heart failure by improving cardiac function and reducing myocardial injury, without increasing adverse reactions.

Key words： Coronary Disease Heart Failure Guanxinning Injection Valsartan Treatment Outcome

Received: 29 January 2026

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xiaorui
	LI Jianhua
	LIU Hui

Cite this article:

ZHANG Xiaorui,LI Jianhua,LIU Hui. Efficacy of Guanxinning Injection Combined with Sacubitril/Valsartan in the Treatment of Coronary Heart Disease with Congestive Heart Failure and Effect on Cardiac Function and Myocardial Injury Markers[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(6): 903-906.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.06.007 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I6/903

[1] 张静,侯少华,徐晶华,等. 冠心病合并充血性心力衰竭患者心率变异、甲状腺激素水平及其与病情的相关性[J].西部医学,2021,33(3):392-395.
[2] 金敏杰. 复方丹参注射液联合加味复元活血汤治疗冠心病合并急性充血性心力衰竭临床研究[J].新中医,2023,55(14):37-42.
[3] 努热曼古丽·阿布都克热木, 宋博凡, 冯俊. 沙库巴曲缬沙坦在心力衰竭治疗中的研究进展[J].中国医药科学, 2021, 11(19): 54-58.
[4] 姚惠, 张清文, 朱坤. 冠心宁注射液联合酒石酸美托洛尔片治疗冠心病心绞痛的效果观察[J].世界中医药, 2020, 15(18): 2751-2754.
[5] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.稳定性冠心病基层诊疗指南(2020年)[J].中华全科医师杂志, 2021,20(3): 265-273.
[6] 王华, 梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 46(10): 760-789.
[7] 中华中医药学会心血管病分会.冠心病稳定型心绞痛中医诊疗专家共识[J].中医杂志,2018,59(5):447-450.
[8] 屈文静,薛东,刘波. 二丁酰环磷腺苷钙联合瑞舒伐他汀治疗冠心病合并心力衰竭的效果及对NT-proBNP、cTn、Gal-3水平的影响[J].中国急救复苏与灾害医学杂志,2024,19(11):1491-1495.
[9] 郭梅芳,白姗,常晓玲,等. 个性化管理联合菜单式健康教育模式在冠心病合并充血性心力衰竭患者中的应用效果[J].河南医学研究,2025,34(22):4178-4182.
[10] 方元实,彭杰成,程辉. 阿利沙坦酯联合美托洛尔治疗对老年冠心病合并慢性充血性心力衰竭患者心室重构及血清脑钠肽水平的影响[J].西北药学杂志, 2025,40(1):159-164.
[11] 孟雅杰,陈嘉怡,李敬超,等. 沙库巴曲缬沙坦钠片治疗冠心病合并慢性心力衰竭的疗效及对患者心功能与炎性因子水平的影响[J].海南医学,2023,34(5):621-624.
[12] 李楠,梁会娟. 冠心宁注射液联合曲美他嗪对冠心病合并心力衰竭病人的心肌保护作用[J].中西医结合心脑血管病杂志,2023,21(10):1841-1844.
[13] 郭颖强, 薛瑞文, 吴维, 等. 冠心宁注射液后处理对心肌缺血再灌注损伤保护作用的临床研究[J].临床心血管病杂志, 2020,36(2):161-165.
[14] 江庆样, 陈国, 陈新华, 等. 血清N末端脑钠肽前体、肌钙蛋白I与慢性充血性心力衰竭不良预后的关系[J].心血管病防治知识, 2025, 15(16): 19-22.